Posted by Michael Wonder on 20 Jan 2016
AbbVie's Venetoclax receives breakthrough therapy designation from FDA in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukaemia
20 January 2016 - Venetoclax is an inhibitor of the B-cell lymphoma-2 protein being developed by AbbVie in partnership with Genentech and Roche.
For more details, go to: http://abbvie.mediaroom.com/2016-01-20-AbbVies-Venetoclax-Receives-Breakthrough-Therapy-Designation-from-FDA-in-Combination-with-Rituximab-for-the-Treatment-of-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia
